Document 3268
 DOCN  M94A3268
 TI    AIDS in HIV1/HIV2 seronegative patient in Yaounde-Cameroon.
 DT    9412
 AU    Zekeng L; Afane ZE; Gurtler L; Ondoa P; Knapp S; Eberle J; Kaptue L;
       Laboratoire d'hematologie, CHU Younde Cameroun.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):115 (abstract no. PA0079). Unique
       Identifier : AIDSLINE ICA10/94369307
 AB    OBJECTIVE: To describe a case of HIV infection in a Cameroonian patient
       antibody negative using commercial available EIA and rapidassays.
       METHODS: Miss A., 24 years old was hospitalized for poor general state,
       productive cough, persistant diarrhoea and oral candidiasis. A chest
       Xray and sputum examination confirmed a pulmonary tuberculosis (TB)
       which was treated with Rifamycine, INH, Ethambutol and Pyrazinamide.
       HIV1+2 serology was requested twice at 3 weeks interval using commercial
       EIA assays (Genclaviamixte HIV1 + 2 Pasteur, Wellcozyme HIV1 + 2 Murex,
       Enzygnost anti HIV1/HIV2 Behring) and rapid assays (HIVSPOTHIV1 +
       2DBL,SUDSHIV1 + 2 Murex). During a third request 3 weeks after, we
       include an EIA HIV1 subtype Oasay (Enzygnost 5180 Behring) which was
       developped using a strain isolated from a Cameroonian AIDS patient in
       1991. Blood was also drawn for PCR and virus isolation from PBMCs.
       RESULTS: The HIV1 + 2 serology remained negative or at most very
       borderline for the 3 trials using commercial assays mentionned above.
       When using the 5180 EIA, the OD was 1.4 with a cut off of 0.267. The
       HIV1 western blot showed p24 and p55 bands with a faint gp41, and
       specific HIV2 EIA also remained negative. The PCR was faintly positive
       using 5180 ENV primer and negative using ENV conventional HIV1 primers.
       The virus was isolated from PBMC after 14 days culture. p24-antigen and
       reverse transcriptase tests were strongly positive. The characterization
       of the genome is going on. CONCLUSION: Isolating HIV from a negative
       patient using commercial available assays shows their limit in detecting
       HIV antibodies to HIV1 subtype 0 and other divergent strains. The
       magnitude of such an issue in Cameroon and neigbouring countries needs
       to be addressed urgently.
 DE    Acquired Immunodeficiency Syndrome/*IMMUNOLOGY/MICROBIOLOGY  Adult
       Cameroon  Case Report  DNA Primers/GENETICS  Female  Genes, env  Human
       HIV Antibodies/BLOOD  HIV Antigens/BLOOD  HIV Seronegativity/*IMMUNOLOGY
       HIV-1/GENETICS/*IMMUNOLOGY/ISOLATION & PURIF
       HIV-2/GENETICS/*IMMUNOLOGY/ISOLATION & PURIF  Leukocytes,
       Mononuclear/MICROBIOLOGY  Polymerase Chain Reaction  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).